Watching The Review Clock: Are US FDA Goal Date Extensions Reason For Optimism?

Novel agents that received three-month user fee goal date extensions have a slightly higher approval rate than novel applications overall.

Stopwatch (shutterstock_157284068)
• Source: Shutterstock

Biogen, Inc. and Eisai Co., Ltd.’s announcement of a three-month extension to the PDUFA goal date for the potential Alzheimer’s disease therapy aducanumab cast a spotlight on what is usually a fairly mundane regulatory event: a three-month extension to the goal date.

Analysts greeted the 29 January 2021 announcement of the new 7 June target with a degree of optimism, noting that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet